The global DNA methylation market is on the verge of a significant surge, with an anticipated market value of USD 1437.5 million in 2023, and projected to skyrocket to USD 5815.49 million by 2033. This remarkable trajectory represents a robust compound annual growth rate (CAGR) of 15% from 2023 onwards.
The anticipated expansion of the DNA methylation market is driven by several critical factors. One of the foremost catalysts is the rising prevalence of cancer globally, which has amplified the need for advanced medical research and diagnostic tools. As the demand for innovative diagnostic solutions intensifies, the role of DNA methylation in cancer research has become increasingly vital.
Grab Your Exclusive Sample Report: Unveiling the Spectacular Growth of the DNA Methylation Market
DNA methylation is a crucial epigenetic process responsible for regulating gene expression. Disruptions in DNA methylation patterns have been associated with various diseases, including cancer, neurological disorders, and autoimmune conditions. As a result, there is a growing demand for DNA methylation analysis tools and services, driving the DNA methylation industry forward.
“We are witnessing a paradigm shift in the understanding and application of DNA methylation in healthcare and medical research,” said FMI. “As the importance of epigenetics becomes increasingly recognized, the DNA methylation market is poised for unprecedented growth, offering significant opportunities for innovation and advancement in the field of personalized medicine.”
The escalating demand for DNA methylation analysis tools and services underscores the need for continued investment in research and development to develop cutting-edge technologies and solutions. Market players are actively focusing on strategic collaborations, product launches, and acquisitions to strengthen their market presence and meet the evolving needs of healthcare professionals and researchers worldwide.
With the global DNA methylation market projected to witness exponential growth in the coming years, stakeholders across the healthcare and life sciences sectors are poised to capitalize on this burgeoning opportunity to drive innovation, improve patient outcomes, and advance medical research.
Key Takeaways from the Market Study:
- By technology, sequencing is expected to possess 35% market share for DNA Methylation Industry in 2023.
- By product, consumables are expected to possess 35% market share for DNA Methylation Industry in 2023.
- By application, clinical research is expected to possess 40% market share for DNA Methylation Industry in 2023.
- By application, diagnostic segment is anticipated to witness the fastest growth in the coming years with a CAGR of 16%.
- By end use, pharmaceutical and biotechnology end-use segment are expected to possess 42% market share for DNA methylation in 2023.
- North America is expected to possess 40% market share for DNA Methylation Industry in 2023.
- Asia Pacific is expected to possess 38% market share for DNA Methylation Industry in 2023.
“Expenditure on research and development along with government funding is expected to accelerate the growth of DNA Methylation Industry.” comments a Future Market Insights analyst.
Discover Our Full Report Can Transform Your Business with Actionable Insights
Competitive Landscape:
Some prominent players in the global DNA Methylation Industry include
- New England Biolabs
- Sysmex Corporation
- Abcam plc.
- F. Hoffmann-La Roche Ltd.
- Diagenode Diagnostics S.A.
- Thermo-Fisher Scientific Inc.
- Agilent Technologies Inc.
- BioRad Laboratories Inc.
- Exact Sciences Corporation
- QIAGEN N.V.
- Active Motif, Inc.
- Illumina Inc.
- EpiGentek Group Inc.
In May 2022, Oxford Nanopore announced integrating Remora, a technique that offers accurate and real-time epigenetic insights with nanopore sequencing software. This would further offer simple access to accurate whole genome methylation detection.
In June 2020, Base Genomics announced of advancing and developing its DNA methylation technology. the aim is to sequence a large amount of epigenetic data from a blood test which could revolutionize the preventative medicine arena.
Key Segments Profiled in the DNA Methylation Industry Survey:
Technology:
- Polymerase Chain Reaction (PCR)
- Microarray
- Sequencing
- Others
Product:
- Consumables
- Kits & Reagents
- Enzymes
- Instruments & Software
Application:
- Gene Therapy
- Clinical Research
- Diagnostics
- Others
End-use:
- Hospital & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Research & Academia
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
